SPTBN2 and ovarian serous cystadenocarcinoma: The results from xCELL suggest that expression of SPTBN2 negatively correlates with the infiltration levels of most immune cells in ovarian serous cystadenocarcinoma and cholangiocarcinoma (Fig. 5b, p < 0.05).